Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have received a consensus rating of “Hold” from the ten analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.00.

A number of analysts have commented on the company. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. BidaskClub downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Needham & Company LLC reiterated a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, April 5th. Finally, HC Wainwright set a $27.00 target price on Lexicon Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 3rd.

Several hedge funds have recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at about $12,582,000. Vanguard Group Inc. increased its stake in shares of Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at about $7,813,000. Point72 Asset Management L.P. bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at about $5,485,000. Finally, Sector Gamma AS bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at about $4,765,000.

Lexicon Pharmaceuticals (NASDAQ LXRX) opened at 15.98 on Monday. The stock’s market cap is $1.68 billion. The firm has a 50-day moving average price of $15.77 and a 200-day moving average price of $15.16. Lexicon Pharmaceuticals has a one year low of $13.41 and a one year high of $19.62.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/17/lexicon-pharmaceuticals-inc-nasdaqlxrx-receives-average-rating-of-hold-from-analysts.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.